Given the rapid spread and global pandemic status of COVID-19, health professionals are increasingly focusing on disease mitigation rather than disease containment. With over 100,000 confirmed cases & 1,500 deaths in the US spread across EVERY state, your odds of contracting COVID-19 are rapidly rising. The safe bet now is to prepare to deal with infection rather than naively hoping to avoid it.

Fortunately, there are steps you can take to limit the harm done by COVID-19 in the increasingly likely event that you eventually become infected. However, since the incubation period of COVID-19 is 2 weeks—during which time you will be unaware of your status—you must be prepared beforehand to act immediately upon diagnosis to limit the severity of your symptoms, using evidence-based dietary supplementation that leverages our collective understanding of the molecular biology of RNA viruses (e.g. coronaviruses).


Crucially, a large body of primary research demonstrates that dietary supplementation with the potent antioxidant N-acetylcysteine (NAC) can inhibit RNA virus replication and reduce the severity of associated diseases [1], [2], [3]. NAC is a simple amino acid whose antioxidant power and bioavailability can be dramatically improved by simple enzymatic modification to N-acetylcysteine ethyl ester (NACET) [4]. This modification of NAC permits unprecedented protection of your blood cells from oxidative damage, thus enabling your body’s immune system to effectively defend your body from the ravages of COVID-19 [5], [6]. NAC itself has low oral bioavailability because it is rapidly metabolized in your liver before it can reach your tissues, especially the lung epithelium which is most at risk for COVID-19 induced oxidative damage. Fortunately, dietary supplementation with NACET allows for more NAC to be produced inside your lung tissue cells where it is needed the most (Fig. 1).

Recent research has demonstrated that NAC has a uniquely potent ability to enhance your body’s antioxidant defense capacity in the context of respiratory diseases

NAC, the simplest Cysteine derivative, has been therapeutically administered in a vast number of studies [7]. NAC was introduced in clinical practice more than 60 years ago. Its antimucolytic effect is due to the reduction of the disulfide bridges of the proteins in mucus. Loss of balance between antioxidant defense and oxidant production in cells, which commonly occurs as a secondary feature in many human diseases including respiratory disease such as COVID-19, is loosely termed “oxidative stress” [8]. Recent research has demonstrated that NAC has a uniquely potent ability to enhance your body’s antioxidant defense capacity in the context of respiratory diseases [9].

Buy NACET today so that you have it when you need it. Boost your NAC levels and protect yourself from the worst symptoms of COVID-19. Review our new article about dosages for NACET.


  1. J. Geiler et al., “N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus,” Biochem. Pharmacol., 2010.
  2. M. Mata, E. Morcillo, C. Gimeno, and J. Cortijo, “N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV),” Biochem. Pharmacol., 2011.
  3. Q. Zhang, Y. Ju, Y. Ma, and T. Wang, “N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia,” Med. (United States), vol. 97, no. 45, p. e13087, Nov. 2018.
  4. D. Giustarini, A. Milzani, I. Dalle-Donne, D. Tsikas, and R. Rossi, “N-Acetylcysteine ethyl ester (NACET): A novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential,” Biochem. Pharmacol., vol. 84, no. 11, pp. 1522–1533, Dec. 2012.
  5. D. Tsikas et al., “S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)–Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview,” Journal of Pharmaceutical Analysis, vol. 8, no. 1. Xi’an Jiaotong University, pp. 1–9, 01-Feb-2018.
  6. A. Böhmer, A. Pich, M. Schmidt, A. Haghikia, and D. Tsikas, “Evidence by chromatography and mass spectrometry that inorganic nitrite induces S-glutathionylation of hemoglobin in human red blood cells,” J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2016.
  7. K. R. Atkuri, J. J. Mantovani, L. A. Herzenberg, and L. A. Herzenberg, “N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency,” Current Opinion in Pharmacology, vol. 7, no. 4. Elsevier, pp. 355–359, 01-Aug-2007.
  8. O. A. Khomich, S. N. Kochetkov, B. Bartosch, and A. V. Ivanov, “Redox biology of respiratory viral infections,” Viruses. 2018.
  9. M. F. McCarty and J. J. DiNicolantonio, “Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus,” Prog. Cardiovasc. Dis., Feb. 2020.


Comments are closed.

By Using This Website You Agree To Our Terms Of Service

FDA Disclaimer • Copyright © • An UMBRELLA Company